Waycross Partners’s Gilead Sciences GILD Stock Holding History

Waycross Partners’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$799K	Hold	5,732	–	–	0.08%	36
2025 Q4	$704K	Hold	5,732	–	–	0.06%	59
2025 Q3	$636K	Hold	5,732	–	–	0.05%	62
2025 Q2	$636K	Buy	+5,732	New	+$610K	0.06%	60
2021 Q4	–	Sell	-14,000	Closed	-$978K	–	87
2021 Q3	$978K	Hold	14,000	–	–	0.62%	58
2021 Q2	$964K	Hold	14,000	–	–	0.51%	55
2021 Q1	$905K	Buy	+14,000	New	+$903K	0.5%	59

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Waycross Partners's GILD Position: Q1 2026 in Review

Waycross Partners held its Gilead Sciences (GILD) position steady in Q1 2026 at 5,732 shares worth $799K. The position accounts for 0.08% of the portfolio, ranked #36.

Waycross Partners first reported a position in GILD in Q1 2021 and has held it in 7 quarters since. The position peaked at $978K in Q3 2021. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Waycross Partners held 5,732 shares of Gilead Sciences worth $799K as of Q1 2026.
Waycross Partners left its Gilead Sciences share count unchanged in Q1 2026.
Gilead Sciences made up 0.08% of Waycross Partners's portfolio in Q1 2026, its #36 holding.
Waycross Partners first reported a position in Gilead Sciences in Q1 2021 and has held it in 7 quarters since.
Waycross Partners's Gilead Sciences position peaked at $978K in Q3 2021.
2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Waycross Partners's 13F filing for Q1 2026, filed 7 May 2026.